BIOMARIN PHARMACEUTICAL INC(BMRN)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
BIOMARIN PHARMACEUTICAL INC (BMRN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BMRN at 58.2/100 on a 32-signal composite quality model, placing it at rank #1,029 of 2,961 stocks — the top half of the AI-ranked universe. BMRN scores in the top quartile across earnings quality (97.4), free cash flow (75.0). Areas of concern include profitability (29.4) and balance sheet strength (39.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BIOMARIN PHARMACEUTICAL INC reports quarterly revenue of $989.7M, net income of $44.8M, an operating margin of 11.2%. Top institutional holders of BMRN by reported 13-F value include BlackRock, DODGE & COX, PRIMECAP MANAGEMENT, based on the most recent SEC filings. BMRN trades on the Nasdaq exchange and files with the SEC under CIK 1048477. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BMRN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOMARIN PHARMACEUTICAL INC directly from SEC EDGAR.
AI Quality Score
58.2/100
AI Rank
#1,029
Revenue
$989.7M
Net Income
$44.8M
Free Cash Flow
$139.3M
Operating Margin
11.2%
BMRN key financials by period
BIOMARIN PHARMACEUTICAL INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$3.2B
$348.9M
12.7%
FY 2024
10-K
$2.9B
$426.9M
17.0%
FY 2023
10-K
$2.4B
$167.6M
7.7%
FY 2022
10-K
$2.1B
$141.6M
7.7%
FY 2021
10-K
$1.8B
$-64.1M
-4.5%
FY 2020
10-K
$1.9B
$854.0M
-2.3%
Institutions holding BMRN
Institutional investors reporting a position in BIOMARIN PHARMACEUTICAL INC on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-05-05 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
BioMarin's Q1 2026 net income fell 43% YoY to $105.5M on $766.2M revenue (+3% YoY) as gross margin compressed 5.2 points due to NAGLAZYME manufacturing charge; Amicus acquisition closed April 2026 for $4.8B.
Biggest Revenue Drivers
VOXZOGO$219.9M+3% YoY
Higher sales volume from new patients initiating therapy across all regions
VIMIZIM$210.2M+12% YoY
Higher sales volume due to timing of orders in countries that place large government orders, primarily Middle East and Latin America
Biggest Revenue Drivers
Total revenue: $766.2M+3% YoY
VOXZOGO$219.9M+3% YoY
Higher sales volume from new patients initiating therapy across all regions
VIMIZIM$210.2M+12% YoY
Higher sales volume due to timing of orders in countries that place large government orders, primarily Middle East and Latin America
NAGLAZYME$130.1M+14% YoY
Higher sales volume due to timing of orders in countries placing large government orders
Other Products$206.0M-7% YoY
PALYNZIQ down 4%, ALDURAZYME down 25%, ROCTAVIAN down 75%, partially offset by BRINEURA up 17% and KUVAN flat
Largest Expense Items
Cost of sales$195.0M+29% YoY
$31.0M charge associated with unsuccessful process qualification campaign to expand NAGLAZYME manufacturing capabilities
Research and development$178.8M+13% YoY
Higher spend on BMN 401, a later-stage clinical program acquired in Q3 2025
Selling, general and administrative$258.3M+25% YoY
Increased spending on global expansion of Enzyme Therapies and VOXZOGO, plus pre-close costs related to Amicus acquisition
Watch Items from the Filing
Three customers represent 15%, 11%, and 10% of Q1 2026 product revenues (36% combined); government order timing creates significant period-to-period variation.
Amicus acquisition closed April 2026 for $4.8B total equity value plus $433M debt repayment, financed with $2.8B secured term loans and $850M 2034 Notes, raising total indebtedness to ~$4.3B post-close.
DOJ subpoena received regarding sponsored testing programs for VIMIZIM and NAGLAZYME; company cooperating but unable to assure outcome of investigation.
ROCTAVIAN voluntarily withdrawn from market in Q1 2026; $240.0M restructuring charge recorded in 2025 related to inventory write-off, asset impairment, and severance.
2027 Notes of $600M outstanding due May 2027 if not converted; company will need to refinance or repay in cash alongside new $2.8B term loan obligations.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
